MO · Full Picture

ALTRIA GROUP, INC. — the full picture

Earnings window · 2026-07-30 to 2026-11-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Dividends and Capital Returns · Buybacks & dividendsPriority 87
    -18.1% cash (realized); 3 sources (press_release, sec_filing, transcript); 2 forward row(s); quote_verified
    Altria's Board authorized a $1 billion expansion of the existing share repurchase program, which now expires December 31, 2027.
  2. Net Income and EPS Performance · Operating income & profitabilityPriority 82
    +27.6% net_income (realized); 4 sources (news, press_release, sec_filing, transcript); structured_verified
    Altria reported net earnings attributable to Altria of $6,999 million and diluted EPS of $4.18 for the nine months ended September 30, 2026, increases of 20.1% and 21.2%, respectively, year over year.
  3. Settlement and FDA Payments · UnclassifiedPriority 78
    -41.7% operating_income; 1 forward row(s); structured_verified
    Altria estimated State Settlement Agreement and FDA user fee charges to cost of sales would average $3.0 billion annually for the next three years, based on current agreements and estimates.
  4. Operating Income and Margins · Operating income & profitabilityPriority 75
    +21.6% operating_income (realized); 2 sources (sec_filing, transcript); structured_verified
    Operating income increased $1,074 million (21.4%) for the six months ended June 30, 2026 versus the six months ended June 30, 2025 due primarily to higher OCI (which includes the impact of a non-cash impairment of the e-vapor reporting unit goodwill in 2025).
  5. Liquidity and Debt Position · Debt, leverage & refinancingPriority 69
    +6.1% liability (realized); 3 sources (news, press_release, sec_filing); 1 forward row(s); structured_verified
    Altria Group has extended its USD 3.0 billion revolving credit agreement to October 24, 2030.
  6. Guidance / Outlook · Guidance & outlookPriority 68
    4 sources (news, press_release, sec_filing, transcript); 10 forward row(s); quote_verified
    Altria raised its 2026 adjusted diluted EPS guidance to $5.66-$5.74, representing 4.5%-6% growth from the 2025 base of $5.42.
  7. Revenue Performance and Mix · Revenue growth & mixPriority 66
    +4.6% revenue (realized); 4 sources (news, press_release, sec_filing, transcript); 2 forward row(s); structured_verified
    The most recent consensus estimate is projecting Altria revenue of $5.3 billion for the upcoming quarter, reflecting a 0.98% rise from the equivalent quarter last year.
  8. Macroeconomic Consumer Pressure · Macroeconomic conditionsPriority 59
    4 sources (news, press_release, sec_filing, transcript); quote_verified
    Altria said macroeconomic uncertainty and inflation pressures led consumers to opt for lower-priced alternatives, contributing to declines in premium cigarette and nicotine-pouch demand.
  9. Premium Cigarette Demand Pressure · Demand, orders & backlogPriority 59
    4 sources (news, press_release, sec_filing, transcript); quote_verified
    Engineers Gate Manager LP significantly reduced its stake in Altria Group by 60.9% in the second quarter.
  10. Balance Sheet and Liquidity · Liquidity & cash positionPriority 57
    +5.5% liability (realized); 2 sources (press_release, transcript); quote_verified
    At September 30, 2026, Altria Group, Inc. had investments in equity securities of $9,326 million, compared with $8,617 million at December 31, 2025.
  11. Operating Cash Flow Trends · Cash flow generationPriority 57
    -6.1% cash (realized); structured_verified
    Altria used $7,657 million of cash in financing activities in the first nine months of 2026, compared with $5,542 million in the first nine months of 2025.
  12. Regulatory Risk · Regulatory action & investigationsPriority 57
    3 sources (news, press_release, transcript); 2 forward row(s); quote_verified
    Helix and NJOY filed legal action against the FDA during Q3 2026 seeking a review process meeting Congress's 180-day timeframe and permission for products with applications pending beyond that timeframe to remain on the market while a new process is established.

Threads by pillar

Revenue & Demand Priority 83 · 7 threads

Costs & Margins Priority 93 · 10 threads

Capital & Balance Sheet Priority 96 · 12 threads

Strategy & Portfolio Priority 43 · 2 threads

Legal, Regulatory & Policy Priority 79 · 8 threads

Guidance & Outlook Priority 68 · 1 thread

Macro & Market Conditions Priority 68 · 4 threads

Management & Governance Priority 25 · 1 thread

Unclassified Priority 95 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-41.7%+41.7%+18.9%
assets+1.1%+1.3%+2.1%
cash-1.1%+1.1%-27.1%
revenue——+6.7%
liability——+11.5%
margin——-2.0%
net_income——+43.8%